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Abstract
Transforming growth factor-b (TGF-b) is a tumor suppressor, the function of which is
compromised in many types of human cancer, including breast cancer. The tumor
suppressive effects of TGF-b are caused by potent inhibition of cell proliferation due to cell
cycle arrest in the G1 phase. Such antiproliferative responses are mediated by a signaling
system that includes two types of cell surface receptors and intracellular signal transducers,
the SMAD proteins. Different molecular mechanisms can lead to loss of antiproliferative
TGF-b responses in tumor cells, including mutations in components of the signaling system
and inhibition of the SMAD signaling pathway by aberrant activities of various regulatory
molecules. Some of these mechanisms will be discussed, with emphasis on their potential
involvement in breast tumorigenesis.
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Introduction
The transforming growth factor-b (TGF-b) family of
polypeptide growth factors regulates cellular processes,
including cell division, differentiation, motility, adhesion,
and death, in virtually all tissues ([1] and references
therein). TGF-b is an important regulator of normal
mammary gland development and function, as well as of
the development and progression of breast tumors. TGF-b
potently inhibits cell cycle progression of epithelial cells,
including those of the lobules and ducts of the mammary
gland, and it thereby controls epithelial cell proliferation
and regression during mammary gland development, and
during and after lactation in the adult gland [2].
In breast cancer, TGF-b has been suggested to play a
dual role [3]. It acts as a tumor suppressor in early stages
of the disease when it inhibits the outgrowth of carcino-
mas in situ via its antiproliferative functions. This has been
demonstrated in transgenic mouse models, in which over-
expression of TGF-b1 (one isoform of TGF-b) is targeted
to the mammary gland, and tumor formation is induced by
concomitant overexpression of TGF-b and administration
of a chemical carcinogen [4]. In later stages of the
disease, TGF-b is believed to promote tumor progression,
in part by enhancing tumor cell motility and invasiveness
[5,6] and the capacity to form metastases [6–8]. Tumor
promoting functions of TGF-b correlate with increased
secretion of TGF-b by the cancer cells during tumor pro-
gression [3].
This apparent switch of the role of TGF-b in the regulation
of tumorigenesis is reflected in changes of tumor cellBreast Cancer Research    Vol 2 No 2 Kretzschmar
responsiveness. Similar to other types of carcinomas, many
malignant breast carcinoma cells have lost most or all sen-
sitivity to TGF-b-induced growth inhibition, while tumor
cells derived from early stages of the disease are usually
inhibited [9]. This loss of antiproliferative responsiveness
thereby predisposes to or causes cancer progression.
TGF-b induces growth inhibition by arresting cells in the G1
phase of the cell cycle, leading in some circumstances to
terminal differentiation or induction of apoptosis [10]. G1
arrest is achieved by several mechanisms that may act in a
complimentary fashion in the same cell, and which include
the transcriptional upregulation of the cyclin-dependent
kinase inhibitors p15Ink4B and p21cip1/waf1, the downregula-
tion of the cyclin-dependent kinase activating phosphatase
Cdc25A, and the downregulation of the proto-oncogene
c-Myc. Together, these events lead to a hypophosphory-
lated, activated state of the pRB tumor suppressor protein,
and thereby to the arrest of the cell cycle in G1.
The antiproliferative response to TGF-b depends on a sig-
naling pathway that is initiated by the ligand-activated
TGF-b receptor complex on the cell surface and is trans-
duced into the nucleus by signaling mediators, the SMAD
proteins [1,11] (Fig. 1). In this pathway, TGF-b binds to a
specific pair of type I and type II receptor serine/threonine
kinases, leading to the transphosphorylation and activation
of the type I receptor (TbR-I) by the type II receptor
(TbR-II). Activated TbR-I then phosphorylates a specific
subset of SMAD proteins, Smad2 and Smad3, which sub-
sequently translocate into the nucleus. On their way to the
nucleus, these receptor-activated SMAD proteins associ-
ate with the related Smad4 protein. Once in the nucleus,
SMAD proteins form functional transcription complexes in
association with DNA binding factors, coactivators, or
corepressors [12].
Resistance to TGF-b-induced growth inhibition in breast
carcinoma cells may be caused by a number of mecha-
nisms, some of which are just starting to become clear. In
this review, I will focus on molecular events that directly
interfere with the TGF-b/SMAD signaling pathway.
Inactivating mutations in components of the
TGF-b b/SMAD signaling pathway
Disruption of the TGF-b/SMAD signaling pathway by
mutation has been observed in several types of human
cancer. TbR-II is inactivated by mutation in a majority of
colon and gastric cancers with microsatellite instability
[13••,14,15] and, to a smaller percentage, also in
microsatellite stable colon cancers [16]. In comparison,
mutations in TbR-II are relatively rare in cancers of the
pancreas, liver, and pituitary gland, and in myelodisplastic
syndrome or endometrial cancers with microsatellite insta-
bility [14,17–20]. Mutations or structural alterations in
TbR-II have not been found in primary human breast carci-
nomas [20,21•,22,23] or breast carcinoma cell lines [24].
Inactivation of TbR-II by mutation therefore appears to be
specifically selected for in gastrointestinal cancers [25].
Homozygous deletions of TbR-I were found in a small per-
centage of pancreatic and biliary adenocarcinomas [26],
and a large deletion mutation was detected in TbR-I in one
case of anaplastic large cell lymphoma [27]. Furthermore,
a polymorphism resulting in a deletion of three residues
from a nine alanine stretch has been observed in some
colorectal and cervical carcinomas, and homozygous carri-
ers of this polymorphism may be at enhanced risk for
cancer development [28,29]. In breast cancer, a point
mutation (S387Y) in TbR-I, which diminishes its signaling
capacity, has been reported in 2 of 31 primary carcinomas
(6%) and 5 of 12 lymph node metastases (42%), indicat-
ing that this mutation may represent an important event in
the progression of breast cancer to malignancy [21•]. This
view has been challenged, however, by another study in
which no mutation at this site was detected in 20 cases of
breast cancer metastases [30•].
Inactivating mutations in SMAD genes are found in a
number of human cancers, with the highest frequency in
pancreatic and colon carcinomas. Smad4/DPC4 was
originally isolated as a tumor suppressor gene on chromo-
some 18q21 that is deleted or mutated in nearly half of all
human pancreatic carcinomas [31••], and much less fre-
quently in other cancers [32–37]. Smad2, which is also
located on 18q21, is mutated in a small number of colon,
head and neck, and lung carcinomas [38••,39–42], but
appears to be unaffected in other types of carcinomas as
well as leukemias and lymphomas [34,35,43–50]. In
breast cancer, inactivating mutations in Smad2 have not
been reported and they are rare in Smad4 [37,51]. Inacti-
vating mutations in Smad3 have not been observed in any
of a large number of tumors, including those from gastroin-
testinal, breast, lung, ovarian, and pancreatic cancers [39,
43,44,48,52–54].
Why inactivating mutations in TbR-II and  Smad4 are
involved in significant proportions of gastrointestinal and
pancreatic cancers, respectively, but are rare in breast
(and other) cancers is currently unclear. It suggests,
however, that activities of these molecules might be
required for the development and/or progression of breast
cancer, and therefore mutational inactivation would not
confer a selective advantage.
Reduced expression of TGF-b b/SMAD signaling
components
In some breast cancer cell lines, limited expression of TbR-II
has been correlated with the lack of TGF-b responsiveness
[55•,56,57•]. Stable expression of TbR-II in such cell lines
can restore TGF-b-induced growth inhibition, indicating that
all other signaling components are functional [55•,57•]. Vari-http://breast-cancer-research.com/content/2/2/107
able expression levels of TbR-II were observed in primary
epithelial cell cultures derived from malignant breast tissue
[58]. In contrast, another study detected no loss of TbR-II
expression in primary breast carcinomas [21•].
In a limited number of cases, reduced expression of TbR-I
has been suggested as the cause for loss of TGF-b-medi-
ated growth inhibition in pancreatic or colon carcinoma
cell lines [59–61] or cells from patients with chronic lym-
phocytic leukemia [62]. However, normal TbR-I expression
was observed in the vast majority of primary epithelial cell
cultures derived from malignant breast tissue [58].
In a panel of both estrogen-responsive and estrogen-insen-
sitive breast carcinoma cell lines, Smad2, Smad3, Smad4,
and TbR-I were all expressed at the mRNA level, with the
exception of one cell line (MDA-MB-468) with a homozy-
gous deletion of Smad4 [63]. TbR-II mRNA could not be
detected in two of the cell lines tested (ZR-75-1 and T47D).
Taken together, these results suggest that limited or no
presence of functional Smad4, TbR-I or TbR-II, due to
mutation or aberrant expression, may contribute to loss of
TGF-b growth inhibition in a small percentage of breast
carcinomas. Aberrations in functional expression of Smad2
and Smad3 are unlikely to play a significant role. Alternative
mechanisms to abolish growth inhibitory responses to
TGF-b must therefore evolve in most breast carcinomas.
Inhibition of the TGF-b b/SMAD pathway by
Ras/MAP-kinase signaling
TGF-b can override the proliferative effects of EGF and
other Ras-activating mitogens in normal epithelial cells.
However, cells harboring oncogenic Ras mutations often
Figure 1
This model schematically illustrates the various molecular mechanisms that can contribute to negative regulation of SMAD signaling and thereby to
a loss of transforming growth factor (TGF)b-induced growth inhibition. Inactivating mutations or loss of expression of components of the
TGFb/SMAD signaling pathway are not depicted here but may also be important. For details, see text.show a loss of TGF-b antiproliferative responses. Onco-
genic Ras can achieve inhibition of TGF-b signaling in
mammary epithelial cells by negatively regulating Smad2
and Smad3; that is, by inhibiting their TGF-b-induced
nuclear accumulation and transcriptional activity [64••].
Acting via Erk MAP kinases, Ras causes phosphorylation
of Smad2 and Smad3 at specific sites in the central por-
tions of the proteins. These sites are separate from the
carboxy terminal sites targeted by TbR-I. Mutation of these
MAP kinase sites in Smad3 yields a Ras-resistant form
that can partially rescue the growth inhibitory response to
TGF-b in Ras-transformed cells [64••,65]. EGF, which acti-
vates MAP-kinase transiently, induces a less extensive
phosphorylation and cytoplasmic retention of Smad2 and
Smad3 [64••]. These results have suggested a mechanism
for counterbalanced regulation of Smad2 and Smad3 by
TGF-b and Ras signals in normal cells, and for the inhibi-
tion of antiproliferative TGF-b functions by hyperactive Ras
in cancer cells. In addition to such direct effects on SMAD
signaling, Ras can also interfere with TGF-b functions at
other levels; for example, by upregulating the activities of
G1 phase cyclin-dependent kinases [66].
Even though oncogenic Ras mutations are relatively rare in
breast cancers (found in about 5% of all cases [67]),
about one-third of all breast cancers display overexpres-
sion or amplification of the HER-2/Neu receptor tyrosine
kinase [68–70]. In addition, the related EGF receptor is
also overexpressed in a significant number of cases [71].
Stimulation of the Ras/MAP-kinase pathway is a major
component of the proliferative signals by these receptors.
Amplification and overexpression of HER-2/Neu and
EGF-R have been correlated with aggressive tumor phe-
notype and poor clinical prognosis [69,72]. It is plausible,
therefore, that one function of oncogenic Ras mutations
and elevated HER-2/Neu or EGF-R activity in breast carci-
nomas is to impede the growth inhibitory function of
TGF-b via phosphorylation of SMAD proteins by Erk
MAP-kinase. Consistent with such a model, an inverse
correlation between the presence of oncogenic Ras muta-
tions and the ability of TGF-b to inhibit cell proliferation
has been observed in a panel of carcinoma cell lines,
derived in this case from colon cancers [64••].
Apparently conflicting results with this model are pre-
sented in a study which proposes that EGF and HGF
signal positively through the Smad2 protein in certain cell
lines, and that Smad2 thereby functions as a common
effector of receptor tyrosine kinase and receptor
serine/threonine kinase signaling [73]. The observed
effects are suggested to be mediated by phosphorylation
of Smad2 at sites that are also phosphorylated in
response to TGF-b but are different from the carboxy ter-
minal sites targeted by TbR-I. A clear evaluation of these
results will have to await the mapping and mutational
analysis of the involved phosphorylation sites. Interactions
between TGF-b signaling and various MAP-kinase path-
ways are currently the subject of intense investigation,
fueled by observations that factors of the TGF-b family and
receptor tyrosine kinase activating factors synergize with
or antagonize each other’s actions during developmental
processes, and that under certain conditions, TGF-b
factors elevate MAP-kinase activities in cultured cells [74].
An interesting example of a tumor cell line that features
more than one mechanism of inhibition of TGF-b/SMAD
signaling has recently been described [65]. The colon car-
cinoma cell line SW480.7 lacks expression of a functional
Smad4 protein and also harbors an activating mutation in
the Ki-Ras oncogene. As expected, this cell line does not
show antiproliferative responses to TGF-b. Furthermore,
exogenous expression of Smad4 does not rescue these
responses [65]. Only the concomitant expression of
Smad4 and a Ras-resistant Smad3 mutant protein
restored antiproliferative TGF-b responses, indicating that
both lack of Smad4 and inhibition of Smad3 through
oncogenic Ras signaling contribute to the repression of
TGF-b/SMAD signaling in this cell line [65]. It is likely that
these two mechanisms have evolved at different stages of
tumor development, with the Ki-Ras mutation being an
earlier event than the Smad4 mutation [75].
Altered expression of TGF-b b/SMAD inhibitory
molecules
Several molecules have been identified that can interfere
with SMAD signaling by competitive protein–protein inter-
actions either in the cytoplasm or the nucleus. Two
members of the SMAD family, Smad6 and Smad7, inhibit
the formation of transcriptionally active SMAD complexes
by ligand-induced association with the receptor complex
[76••–78••] or Smad4 [79••]. Association with the receptor
complex prevents the interaction between activated TbR-I
and its SMAD substrates, thereby blocking the TGF-b-
induced phosphorylation and activation of Smad2 and
Smad3. One physiological function of these inhibitory
SMAD proteins might be to provide a negative feedback
regulation of TGF-b family signaling [78••,80,81]. Northern
blot and in situ hybridization analyses indicated that
Smad6 and Smad7 are overexpressed in pancreatic
cancer tissues and cell lines, suggesting that elevated
expression of inhibitory SMAD proteins may contribute to
the loss of growth inhibitory TGF-b responses in pancre-
atic carcinomas [82,83•]. In other studies, however, no
increased expression of Smad7 in a panel of pancreatic
carcinoma cell lines [44] and no clear differences in
Smad6/7 immunostaining of epithelial cells from normal
and tumor tissues of the colon were observed [84]. There
have been no reports as yet concerning expression levels
of Smad6 and Smad7 in breast tissues.
Very recently, a novel mechanism of interference with
certain TGF-b responses emerged. Several SMAD-inter-
Breast Cancer Research    Vol 2 No 2 Kretzschmaracting proteins were identified that serve as transcriptional
corepressors in the TGF-b response [85••–87••,88,89••,
90••]. Two of these, the related proto-oncoproteins c-Ski
and c-SnoN, associate with Smad2, Smad3, or Smad4 in
the nucleus to repress the ability of TGF-b-activated
SMAD complexes to activate transcription [85••–87••,88,
89••]. Both c-Ski and c-SnoN achieve this repression by
recruitment of the transcriptional corepressors N-CoR and
mSin3 [91], which in turn associate with histone deacety-
lases, thereby leading to the formation of a repressive
SMAD complex on the target promoter. Similar to a model
proposed for another SMAD corepressor, TGIF [90••], the
recruitment of c-Ski and c-SnoN is likely to compete with
binding of the transcriptional coactivators p300 or CBP
that possess histone acetyl transferase activity. The acety-
lation state of core histones plays a critical role in tran-
scriptional regulation [92]. Thus, the balance between
SMAD corepressors and coactivators might be important
in determining the transcriptional activities of nuclear
SMAD complexes. Overexpression of c-Ski is thought to
be sufficient for oncogenic activation [93], and elevated
expression of c-Ski was detected in several tumor cell
lines derived from neuroblastoma, melanoma and prostate
cancer [94,95]. A thorough analysis of expression levels of
c-Ski or c-SnoN in normal and cancerous breast tissue
has not been reported, but the recent identification of their
involvement in TGF-b signaling warrants closer investiga-
tion of this issue. Furthermore, a recent study suggested
that c-Ski expression is upregulated in response to estro-
gen signaling in epithelial cells of the uterus [96], raising
the possibility that c-Ski might also be involved in the inter-
actions between estrogen and TGF-b in breast cancer.
A nuclear zinc-finger protein, Evi-1 is involved in leukemic
transformation of hematopoietic cells subsequent to chro-
mosomal translocations that lead to expression of an
AML1/Evi-1 fusion product under the control of the AML1
promoter [97]. The biological functions of Evi-1 are not
well defined, but one way of contributing to a transformed
phenotype may be through its ability to inhibit
TGF-b/SMAD signaling [98••]. Evi-1 is proposed to asso-
ciate specifically with the Smad3 protein, thereby prevent-
ing DNA binding and transcriptional activity of Smad3
containing complexes. Evi-1 or the AML1/Evi-1 fusion
protein can suppress TGF-b-induced growth inhibition
when expressed in lung epithelial or myeloid cells
[98••,99]. It has been suggested that Evi-1 might also be
involved in solid tumors since overexpression has been
observed in ovarian cancer samples [100] and Evi-1
causes transformation when exogenously expressed in
fibroblasts [101,102]. Aberrant expression of Evi-1 in
breast cancer, however, has not been reported to date.
Another recent addition to the growing list of molecules
that can regulate TGF-b/SMAD signaling by direct associ-
ation with one of the signaling components is the
pseudoreceptor BAMBI [103••]. BAMBI was isolated by
an expression screen for molecules involved in BMP4 (a
member of the TGF-b family) signaling. BAMBI is related
to the TGF-b family type I receptors but lacks an intracellu-
lar kinase domain. Its intracellular domain, however, con-
tains the homodimerization interface that allows BAMBI to
form complexes with type I receptors, thereby preventing
the formation of functional type I receptor homodimers
[103••]. Compared with nonmetastatic melanoma cell lines
and normal tissues, the expression of BAMBI in certain
metastatic melanoma cell lines is strongly reduced [104].
It will be important to confirm this observation in primary
melanoma tissue and in other types of tumors, such as
breast cancer, in which a loss of BAMBI may enhance the
tumorigenic activity of TGF-b.
Interference with TGF-b b/SMAD responses
downstream of SMAD proteins
The antiproliferative response of tumor cells to TGF-b can
also be affected by aberrant expression or inactivation of
cell cycle regulators that function downstream of or inde-
pendently of the TGF-b/SMAD pathway. Such alterations
are frequently found in human breast tumors and they
include increased expression of CyclinD1, CyclinE, MDM2,
or c-Myc, decreased expression of p16INK4A or p27Kip1, and
mutations in pRB or p53 [68]. For more detailed discussion
of these alterations, see [68,105].
Conclusions
A number of different molecular mechanisms have been
described that might contribute to the development of
resistance to the growth inhibitory effects of TGF-b in
breast carcinoma cells. More work needs to be carried out
to determine the relative significance of these various
mechanisms for the etiology of breast cancer. Each individ-
ual case of breast cancer might feature a specific combina-
tion of these mechanisms. The nature of this combination is
likely to influence the course of the disease by determining
the extent of resistance to TGF-b-induced growth inhibition
at different stages and by the manifestation of other TGF-b
responses that may contribute to the invasive and metasta-
tic potential of the tumor cells. For example, while inactivat-
ing mutations in TbR-II should abolish all TGF-b responses,
inhibition of SMAD signaling by various mechanisms will
block SMAD-dependent responses, such as growth inhibi-
tion, to varying extents and will allow potential SMAD-inde-
pendent TGF-b effects to remain intact. The continued
elucidation of TGF-b signaling and its molecular and func-
tional interactions with oncogenic events involved in breast
cancer has the potential to lead to novel ways of treating
the disease; for example, by selectively restoring tumor
suppressive TGF-b functions and/or inhibiting tumor pro-
moting TGF-b functions.
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